Global Transthyretin Amyloidosis Treatment Market Report and Forecast 2023-2031

The global transthyretin amyloidosis treatment market size was valued at USD 5.07 billion in 2022 and is projected to grow at a CAGR of 7.47% during the forecast period of 2023-2031 to reach a value of USD 9.66 billion by 2031. The market growth can be attributed to the increasing prevalence of transthyretin amyloidosis and the rising awareness about the condition.

Global Transthyretin Amyloidosis Treatment Market: Introduction

Transthyretin amyloidosis treatment involves managing the symptoms and complications associated with the progressive disease caused by the build-up of abnormal transthyretin protein. The condition affects multiple organs and body systems, resulting in a variety of symptoms. Treatment options include medications, lifestyle modifications, and supportive therapies. The increasing prevalence of transthyretin amyloidosis, along with rising awareness and the development of innovative treatment options, is driving the demand for transthyretin amyloidosis treatment.

Advancements in diagnostics and therapeutics have played a significant role in the growth of the transthyretin amyloidosis treatment market. Improved diagnostic techniques have enabled more accurate identification of the condition, leading to better management and treatment outcomes. Moreover, the development of targeted therapies and a better understanding of the underlying mechanisms of the condition contribute to the market's growth. Increased research and investment in transthyretin amyloidosis treatment options have also fostered market expansion.

The transthyretin amyloidosis treatment market is expected to continue to grow in the coming years, as awareness of the condition increases, and new treatment options and technologies are developed to meet the needs of patients with transthyretin amyloidosis. However, there are still significant challenges in diagnosing the condition and providing appropriate treatment, particularly in low- and middle-income countries, where access to healthcare services may be limited.

Transthyretin Amyloidosis Epidemiology

Transthyretin amyloidosis is a rare condition, affecting approximately 1 in 100,000 people worldwide. The disease can affect people of all ages, but it is most diagnosed in middle-aged adults. The increasing prevalence of the condition and the growing demand for effective treatment options are driving the growth of the transthyretin amyloidosis treatment market.

Transthyretin Amyloidosis Treatment Market Segmentations

The market can be segmented based on drug type, diseases type, distribution channel, and region:

Market Breakup by Drug Type

• Tafamidis
• Diflunisal
• Patisiran
• Inotersen
• Others

Market Breakup by Diseases Type

• Hereditary Type Transthyretin Amyloidosis
• Wild Type Transthyretin Amyloidosis

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Transthyretin Amyloidosis Treatment Market Analysis

The global transthyretin amyloidosis treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of transthyretin amyloidosis, rising awareness about the condition, and the growing demand for innovative treatment options. North America is currently the largest market for transthyretin amyloidosis treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of transthyretin amyloidosis, a well-established healthcare infrastructure, and strong investment in research and development.

Asia Pacific is another region that is experiencing significant growth in the transthyretin amyloidosis treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of transthyretin amyloidosis, and the growing adoption of innovative treatment options. In addition, government initiatives to address the condition are helping to drive the growth of the market in the region.

Key Players in the Global Transthyretin Amyloidosis Treatment Market

The report provides a detailed analysis of the key players involved in the transthyretin amyloidosis treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

• Sorrento Therapeutics, Inc
• Astellas Pharma Inc
• AstraZeneca plc
• Alexion Pharmaceuticals, Inc
• Spectrum Pharmaceuticals, Inc
• Pfizer Inc
• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc
• Eidos Therapeutics, Inc
• Corino Therapeutics, Inc
• Prothena Corporation plc